GWPH GW Pharmaceuticals Plc

+0.35  (0%)
Previous Close 110.81
Open 110.57
Price To book 6.73
Market Cap 2815529288
Shares 25,328,619
Volume 141,049
Short Ratio 9.13
Av. Daily Volume 357,435

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released February 7, 2017.
Tetrahydrocannabinol (THC) and cannabidiol (CBD)
Glioblastoma Multiform- cancer
Phase 2 trials to be initiated 1H 2018.
GWP42006 (CBDV)
Rett syndrome
Phase 3 initiated December 2016.
Infantile spasms (IS)
Phase 2 data released September 2015. Currently evaluating next steps
Phase 2 trial did not meet endpoint
Type 2 diabetes
Phase 3 trials failed. Evaluating whether there are any next steps
Cancer pain
Phase 2 initiated May 2015. Data due late 2017 or early 2018.
GWP42006 (CBDV)
Second Phase 3 trial initiated mid April 2015. Trial continues to enroll as of August 2017.
Dravet Syndrome
Top line Phase 3 data released March 2016 met primary endpoint. NDA Filing due October 2017.
Dravet Syndrome
First Phase 3 trial data released June 2016. Data from second Phase 3 trial also met endpoint - September 2016. NDA Filing due October 2017.
Lennox-Gastaut syndrome (LGS)
Phase 3 data due 2018.
Tuberous Sclerosis Complex
Phase 2 trial did not meet primary endpoint - noted February 7, 2017.
Spasticity due to cerebral palsy

Latest News

  1. 4 Medical Product Stocks Likely to Top Q3 Earnings Estimates
  2. These 6 Stocks Make Up 58% of the First-Ever Marijuana ETFs Holdings
  3. For Early Success in Cannabis Look Outside the Box
  4. Pot Stock Winners of the Week
  5. This Potential Billion-Dollar Marijuana-Based Drug Suddenly Finds Itself in Deep Trouble
  6. Today's Research Reports on Trending Tickers: GW Pharmaceuticals and Zogenix
  7. A Drug That May Be Better Than Marijuana Sent This Company's Stock Soaring 196% in September
  8. How Risky Is GW Pharmaceuticals Stock After Zogenix's Big News?
  9. Zogenix Stock Nears 7-Year High On Excitement Over Epilepsy Drug
  10. Zogenix Soars 10% Today Despite Diluting Investors
  11. ETFs with exposure to GW Pharmaceuticals Plc : October 2, 2017
  12. Today's Research Reports on Stocks to Watch: GW Pharmaceuticals and Zogenix Inc.
  13. This U.S. Marijuana Stock Is Arguably the Best on the Market -- and It's Dirt Cheap
  14. A Tiny Biotech Just Dealt a Big Blow to Marijuana's Use in Epilepsy
  15. Biotech Nearly Triples On Seizure Drug, Hitting Rival GW Pharma
  16. Why GW Pharmaceuticals, Louisiana-Pacific, and IAMGOLD Slumped Today
  17. Zogenix (ZGNX) Stock Skyrocketed Over 170% Today: Here's Why
  18. Why Zogenix Inc. Stock More Than Doubled Today
  19. Zogenix Soars After Epilepsy Drug Meets Primary Endpoint -Biotech Movers
  20. Should You Invest in This Marijuana ETF?